Recent Finacing
Recent Raise
Arixa Pharmaceuticals develops orally bioavailable prodrugs of intravenous-only beta-lactamase inhibitors, including ARX-1796 (an oral avibactam prodrug), with preclinical high oral absorption and patents.
Focus Areas
Total Raised
Funding round
See the team members at Arixa Pharmaceuticals.
